Market Cap 64.12M
Revenue (ttm) 68.70M
Net Income (ttm) 7.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.44%
Debt to Equity Ratio 0.66
Volume 144,500
Avg Vol 87,086
Day's Range N/A - N/A
Shares Out 11.79M
Stochastic %K 89%
Beta 1.72
Analysts Strong Sell
Price Target $29.40

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 314 5512
Fax: 480 393 5553
Address:
302 East Pettigrew St., Suite A-100, Durham, United States
JG101
JG101 Oct. 3 at 4:08 AM
$DTIL They seem to suggest patient # 1 is doing well and functionally cured but don’t expand on the other patients treated since then. https://firstwordpharma.com/story/6229724
1 · Reply
piton72
piton72 Oct. 2 at 12:01 PM
$DTIL iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting https://www.businesswire.com/news/home/20251002843309/en/iECURE-to-Present-OTC-HOPE-Clinical-Trial-Data-of-ECUR-506-in-Ornithine-Transcarbamylase-Deficiency-at-the-European-Society-of-Gene-Cell-Therapy-Annual-Congress-and-the-American-Society-
0 · Reply
kubota2323
kubota2323 Oct. 1 at 2:52 PM
$DTIL https://www.nasdaq.com/articles/precision-biosciences-dtil-price-target-increased-1913-3706
0 · Reply
piton72
piton72 Sep. 30 at 11:09 AM
$DTIL Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end of 2025; clinical data anticipated in 2026- https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-late-breaking-poster-1
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 25 at 2:11 PM
$DTIL dumping started
1 · Reply
MariaVonsoosten855
MariaVonsoosten855 Sep. 21 at 9:11 AM
$DTIL Biotech with gene editing. Pre-revenue speculation. High risk/reward setup. No pattern.
0 · Reply
RBLTG
RBLTG Sep. 19 at 1:23 PM
$DTIL - Azer-cel response rate increases to 81% https://x.com/TeamImugene/status/1968497419408351418
0 · Reply
JG101
JG101 Sep. 18 at 12:45 AM
$DTIL Interesting article on Precision Bio’s use of ARCUS in Hepatitis B: https://crisprmedicinenews.com/news/arcus-gene-editor-shows-promise-against-hepatitis-b/
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 15 at 6:39 PM
$DTIL best garbage company to lose your money. Not even pump. Slowly raising 50 cents for a month and dump the same within one or two days.
0 · Reply
FloatTommy
FloatTommy Sep. 15 at 8:51 AM
$DTIL Positioned to benefit from sector tailwinds; watch execution and margins
0 · Reply
Latest News on DTIL
JG101
JG101 Oct. 3 at 4:08 AM
$DTIL They seem to suggest patient # 1 is doing well and functionally cured but don’t expand on the other patients treated since then. https://firstwordpharma.com/story/6229724
1 · Reply
piton72
piton72 Oct. 2 at 12:01 PM
$DTIL iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting https://www.businesswire.com/news/home/20251002843309/en/iECURE-to-Present-OTC-HOPE-Clinical-Trial-Data-of-ECUR-506-in-Ornithine-Transcarbamylase-Deficiency-at-the-European-Society-of-Gene-Cell-Therapy-Annual-Congress-and-the-American-Society-
0 · Reply
kubota2323
kubota2323 Oct. 1 at 2:52 PM
$DTIL https://www.nasdaq.com/articles/precision-biosciences-dtil-price-target-increased-1913-3706
0 · Reply
piton72
piton72 Sep. 30 at 11:09 AM
$DTIL Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end of 2025; clinical data anticipated in 2026- https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-late-breaking-poster-1
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 25 at 2:11 PM
$DTIL dumping started
1 · Reply
MariaVonsoosten855
MariaVonsoosten855 Sep. 21 at 9:11 AM
$DTIL Biotech with gene editing. Pre-revenue speculation. High risk/reward setup. No pattern.
0 · Reply
RBLTG
RBLTG Sep. 19 at 1:23 PM
$DTIL - Azer-cel response rate increases to 81% https://x.com/TeamImugene/status/1968497419408351418
0 · Reply
JG101
JG101 Sep. 18 at 12:45 AM
$DTIL Interesting article on Precision Bio’s use of ARCUS in Hepatitis B: https://crisprmedicinenews.com/news/arcus-gene-editor-shows-promise-against-hepatitis-b/
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 15 at 6:39 PM
$DTIL best garbage company to lose your money. Not even pump. Slowly raising 50 cents for a month and dump the same within one or two days.
0 · Reply
FloatTommy
FloatTommy Sep. 15 at 8:51 AM
$DTIL Positioned to benefit from sector tailwinds; watch execution and margins
0 · Reply
JG101
JG101 Sep. 14 at 5:00 AM
$DTIL Recent data presented for first 2 cohorts of patients. So far so good! https://precisionbiosciences.com/wp-content/uploads/2025/09/ICE-HBV-forum_FINAL.pdf
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 12 at 3:31 PM
$DTIL scam company
1 · Reply
Impatient_Investor
Impatient_Investor Sep. 12 at 2:35 PM
$DTIL garbage fell again
0 · Reply
ShurXiJinping
ShurXiJinping Sep. 12 at 11:11 AM
0 · Reply
piton72
piton72 Sep. 12 at 11:06 AM
$DTIL Precision BioSciences Presents Data from the Phase 1 E 09/12/2025 - 01:01 PM DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany, on September 12th. “We are excited to present the progress for the ELIMINATE-B trial with the HBV community at this year’s ICE-HBV symposium following our data update on August 6th,” said Cassie Gorsuch, PhD, Chief Scientific Officer at Precision BioSciences https://www.stocktitan.net/news/DTIL/precision-bio-sciences-presents-data-from-the-phase-1-eliminate-b-542do9bbxkzl.html
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 8 at 11:16 AM
$DTIL Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042
0 · Reply
piton72
piton72 Sep. 8 at 11:06 AM
$DTIL - Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- - Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025- https://www.businesswire.com/news/home/20250908011531/en/Precision-BioSciences-Announces-U.S.-Patent-Covering-PBGENE-HBV-for-Chronic-Hepatitis-B-and-Updates-Program-Status
0 · Reply
JG101
JG101 Sep. 4 at 11:20 PM
1 · Reply
Berakhot
Berakhot Sep. 4 at 3:38 PM
0 · Reply
JG101
JG101 Sep. 1 at 1:58 PM
$DTIL Fresh off the press!
1 · Reply
Impatient_Investor
Impatient_Investor Aug. 29 at 7:11 PM
1 · Reply
Impatient_Investor
Impatient_Investor Aug. 29 at 3:27 PM
$DTIL in 2050
1 · Reply